Promising combo targets hard-to-treat breast cancer

NCT ID NCT04556773

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other anti-cancer medicines in people with metastatic HER2-low breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the cancer's growth. About 138 adults with this type of breast cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

Research Site

Commack, New York, 11725, United States
Research Site

Harrison, New York, 10604, United States
Research Site

New York, New York, 10029, United States
Research Site

New York, New York, 10065, United States
Research Site

Uniondale, New York, 11553, United States
Research Site

Chapel Hill, North Carolina, 27514, United States
Research Site

Chattanooga, Tennessee, 37404, United States
Research Site

Germantown, Tennessee, 38138, United States
Research Site

Fort Worth, Texas, 76104, United States
Research Site

Melbourne, 3000, Australia
Research Site

Westmead, 2145, Australia
Research Site

Edegem, 2650, Belgium
Research Site

Leuven, 3000, Belgium
Research Site

Ottignies, 1340, Belgium
Research Site

Goiânia, 74605-070, Brazil
Research Site

Porto Alegre, 90035-003, Brazil
Research Site

Porto Alegre, 90110-270, Brazil
Research Site

São Paulo, 03102-002, Brazil
Research Site

São Paulo, 04543-000, Brazil
Research Site

Kelowna, British Columbia, V1Y 5L3, Canada
Research Site

Québec, Quebec, G1J 1Z4, Canada
Research Site

Villejuif, 94805, France
Research Site

Monterrey, 64710, Mexico
Research Site

Moscow, 115478, Russia
Research Site

Moscow, 143442, Russia
Research Site

Saint Petersburg, 199226, Russia
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Kaohsiung City, 82445, Taiwan
Research Site

Taichung, 40443, Taiwan
Research Site

Taipei, 100, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

Taipei, 114, Taiwan
Research Site

Taipei, 235, Taiwan
Research Site

Taoyuan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.